Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Prognosis and appropriate treatment goals for older adults with diabetes vary greatly according to frailty. It is now recognised that changes may be needed to diabetes management in some older people. Whilst there is clear guidance on the evaluation of frailty and subsequent target setting for people living with frailty, there remains a lack of formal guidance for healthcare professionals in how to achieve these targets. The management of older adults with type 2 diabetes is complicated by comorbidities, shortened life expectancy and exaggerated consequences of adverse effects from treatment. In particular, older adults are more prone to hypoglycaemia and are more vulnerable to its consequences, including falls, fractures, hospitalisation, cardiovascular events and all-cause mortality. Thus, assessment of frailty should be a routine component of a diabetes review for all older adults, and glycaemic targets and therapeutic choices should be modified accordingly. Evidence suggests that over-treatment of older adults with type 2 diabetes is common, with many having had their regimens intensified over preceding years when they were in better health, or during more recent acute hospital admissions when their blood glucose levels might have been atypically high, and nutritional intake may vary. In addition, assistance in taking medications, as often occurs in later life following implementation of community care strategies or admittance to a care home, may dramatically improve treatment adherence, leading to a fall in glycated haemoglobin (HbA1c) levels. As a person with diabetes gets older, simplification, switching or de-escalation of the therapeutic regimen may be necessary, depending on their level of frailty and HbA1c levels. Consideration should be given, in particular, to de-escalation of therapies that may induce hypoglycaemia, such as sulphonylureas and shorter-acting insulins. We discuss the use of available glucose-lowering therapies in older adults and recommend simple glycaemic management algorithms according to their level of frailty.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons
Podsiadlo, D., & Richardson, S. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb01616.x · Cited by 14,418 · cited 1×
“There are several ways to assess frailty, but tools like the electronic Frailty Index (eFI) [10], Rockwood scale [10] and Timed up and Go [11, 12] can be used to confirm clinical suspicion.”
MethodClegg, A., Young, J., Iliffe, S., Rikkert, M. O., & Rockwood, K. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62167-9 · Cited by 9,503
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 1×
“Many learn to recognise the symptoms and self-manage impending events, but repeated exposure to hypoglycaemia can lead to impaired counterregulation and ‘hypoglycaemia unawareness’, such that symptoms become attenuated and/or manifest only at very low glucose levels, rendering the person less able to respond [32].”
BackgroundAge-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases
Kalyani, R. R., Corriere, M., & Ferrucci, L. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70034-8 · Cited by 1,102 · cited 1×
“Mild exercise is likely to reduce muscle atrophy [30, 31] and improve quality of life (QoL).”
BackgroundBonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933 · cited 1×
“In the landmark ACCORD trial, the risk of severe hypoglycaemia increased with age and, for participants reporting severe hypoglycaemia, mortality was increased threefold [41].”
BackgroundA meta-analysis of randomized controlled trials: Efficacy of selenium treatment for sepsis
Li, S., Tang, T., Guo, P., Zou, Q., Ao, X., Hu, L., & Tan, L. (2019) · Medicine · doi:10.1097/md.0000000000014733 · Cited by 802
Accelerated Loss of Skeletal Muscle Strength in Older Adults With Type 2 Diabetes
Park, S. W., Goodpaster, B. H., Strotmeyer, E. S., Kuller, L. H., Broudeau, R., Kammerer, C., de Rekeneire, N., Harris, T. B., Schwartz, A. V., Tylavsky, F. A., et al. (2007) · Diabetes Care · doi:10.2337/dc06-2537 · Cited by 766
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s009 · Cited by 739
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682 · cited 14×
“The treatments for type 2 diabetes with the greatest propensity for causing hypoglycaemia are insulin and the insulin secretagogues: sulphonylureas (SUs) and glinides.”
BackgroundResultInfluentialRosenstock, J., Kahn, S. E., Johansen, O. E., Zinman, B., Espeland, M. A., Woerle, H. J., Pfarr, E., Keller, A., Mattheus, M., Baanstra, D., et al. (2019) · JAMA · doi:10.1001/jama.2019.13772 · Cited by 612
Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study
Aroda, V. R., Edelstein, S. L., Goldberg, R. B., Knowler, W. C., Marcovina, S. M., Orchard, T. J., Bray, G. A., Schade, D. S., Temprosa, M. G., White, N. H., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3754 · Cited by 536
State of the art paper Sulfonylureas and their use in clinical practice
Sola, D., Rossi, L., Schianca, G. P. C., Maffioli, P., Bigliocca, M., Mella, R., Corlianò, F., Fra, G. P., Bartoli, E., & Derosa, G. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.53304 · Cited by 514
An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus
Hsia, D. S., Grove, O., & Cefalu, W. T. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000311 · Cited by 508
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4127 · Cited by 412
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
Lewis, J. D., Habel, L. A., Quesenberry, C. P., Strom, B. L., Peng, T., Hedderson, M. M., Ehrlich, S. F., Mamtani, R., Bilker, W., Vaughn, D. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.7996 · Cited by 320
Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
Zhu, Z.-N., Jiang, Y.-F., & Ding, T. (2014) · Bone · doi:10.1016/j.bone.2014.08.010 · Cited by 253
Red meat intake and risk of ESRD
Lew, Q.-L. J., Jafar, T. H., Koh, H. W. L., Jin, A., Chow, K. Y., Yuan, J.-M., & Koh, W.-P. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030248 · Cited by 222 · cited 1×
“However, it should be noted that there are potential disadvantages associated with high protein intake: for example, red meat intake may increase the risk of end-stage renal disease [26].”
BackgroundRodriguez‐Mañas, L., Laosa, O., Vellas, B., Paolisso, G., Topinkova, E., Oliva‐Moreno, J., Bourdel‐Marchasson, I., Izquierdo, M., Hood, K., Zeyfang, A., et al. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12432 · Cited by 180 · cited 1×
“As it is now clear that the functional deficits associated with frailty in older adults with diabetes can be reversed [28], it is important that older adults with type 2 diabetes are encouraged to exercise regularly, if such activities can be carried out safely [24].”
BackgroundSelf-citationPathak, R. D., Schroeder, E. B., Seaquist, E. R., Zeng, C., Lafata, J. E., Thomas, A., Desai, J., Waitzfelder, B., Nichols, G. A., Lawrence, J. M., et al. (2016) · Diabetes Care · doi:10.2337/dc15-0858 · Cited by 140
Billington, E. O., Grey, A., & Bolland, M. J. (2015) · Diabetologia · doi:10.1007/s00125-015-3660-2 · Cited by 133
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
Simes, B. C., & MacGregor, G. G. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s212003 · Cited by 103
Effects of TZD use and discontinuation on fracture rates in ACCORD bone study
Schwartz, A. V., Chen, H., Ambrosius, W. T., Sood, A., Josse, R. G., Bonds, D. E., Schnall, A. M., Vittinghoff, E., Bauer, D. C., Banerji, M. A., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1215 · Cited by 85
Abdelhafiz, A. H., & Sinclair, A. J. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.11.011 · Cited by 72
Self-citationLiu, G., Chen, Y., Yang, Y., Yang, K., Liang, J., Wang, S., & Gan, H. (2017) · Geriatrics & Gerontology International · doi:10.1111/ggi.13110 · Cited by 54 · cited 1×
“Frail older people with diabetes may also suffer from malnutrition or sarcopenia [22, 23].”
BackgroundMcCoy, R. G., Lipska, K. J., Van Houten, H. K., & Shah, N. D. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001007 · Cited by 51
Cauza, E., Strehblow, C., Metz-Schimmerl, S., Strasser, B., Hanusch-Enserer, U., Kostner, K., Dunstan, D., Fasching, P., & Haber, P. (2009) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-009-0641-4 · Cited by 36
Heller, S. R., DeVries, J. H., Wysham, C., Hansen, C. T., Hansen, M. V., & Frier, B. M. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13708 · Cited by 18
Strain, W. D., & Griffiths, J. (2021) · British Journal of Diabetes · doi:10.15277/bjd.2021.292 · Cited by 16 · cited 9×
“9% whilst having no impact in younger populations [57].”
BackgroundInfluentialSelf-citation
Cited by
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
Type 2 diabetes and impaired physical function: a growing problem
Ahmad, E., Sargeant, J. A., Yates, T., Webb, D. R., & Davies, M. J. (2022) · Diabetology · doi:10.3390/diabetology3010003 · Cited by 52
Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit/risk balance?
Scheen, A. J., & Bonnet, F. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101419 · Cited by 51
Individualizing diabetes care in older persons with multimorbidity
Sloane, P. D., & Pandya, N. (2021) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2021.07.019 · Cited by 8
Practical Approaches to Continuous Glucose Monitoring in Primary Care: A UK-Based Consensus Opinion
Fernando, K., Alabraba, V., Welsh, J. B., Seidu, S., Strain, W. D., Bell, H. E., Davies, S., & Evans, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01706-x · Cited by 7
Self-citation
Metadata
- Authors
- Strain, W. D., Down, S., Brown, P., Puttanna, A., & Sinclair, A.
- Venue
- Diabetes Therapy
- Published
- 2021-04-08
- Volume
- 12
- Issue
- 5
- Pages
- 1227-1247
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- OpenAlex
- W3146712429
- Cited by
- 194
- References
- 31
- FWCI
- 18.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.